Jazz Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations

Jazz Pharmaceuticals (NASDAQ:JAZZ) Full Year 2024 Results

Key Financial Results

• Revenue: US$4.07b (up 6.1% from FY 2023).
• Net income: US$560.1m (up 35% from FY 2023).
• Profit margin: 14% (up from 11% in FY 2023).
• EPS: US$9.06 (up from US$6.55 in FY 2023).

JAZZ Post-Clinical Trial Products

• Approved (during full year): 1.
• Launched (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Jazz Pharmaceuticals EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 6.6%.

Looking ahead, revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 6.8% from a week ago.

Risk Analysis

Be aware that Jazz Pharmaceuticals is showing 2 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.